Dorsey & Whitney LLP | Global | 22 Aug 2014
Joel Esquenazi and Carlos Rodriguez, whose convictions for FCPA and other violations were affirmed by the 11th Circuit in May 2014, have filed a…
Dorsey & Whitney LLP | USA | 29 Aug 2013
Wal-Mart announced that it in fiscal year 2014, it expects to spend over $300 million investigating possible violations of the U.S. Foreign Corrupt…
Dorsey & Whitney LLP | Global, United Kingdom, USA | 21 Jun 2013
French oil and gas giant Total SA has entered into a three-year deferred prosecution agreement ("DPA") with the U.S. Department of Justice ("DOJ") to…
Dorsey & Whitney LLP | Global, United Kingdom, USA | 21 Dec 2012
Several U.S. mayors are on trial for, under investigation for, or have just been found guilty of charges related to extortion and bribery. A brief rundown:…
Dorsey & Whitney LLP | Global, USA | 17 Sep 2012
Canadian-based Nordion, Inc. has indicated to US and Canadian regulators that it may have uncovered possible violations of the FCPA and the corresponding Canadian anti-corruption statute, the Canadian Corruption of Foreign Public Officials Act. Nordion, based in Ottawa, supplies medical isotopes and had revenue of $274 million in the US in 2011.
Dorsey & Whitney LLP | USA | 19 Jul 2012
On June 11, 2012, the US Supreme Court granted certiorari to hear Amgen Inc. v. Connecticut Retirement Plans & Trust Funds, a case involving two questions that could have a substantial impact on securities class actions.
Dorsey & Whitney LLP | USA | 22 Jun 2012
The SEC has been investigating Angolan presalt company Cobalt International Energy, a US company, since November 2011.
Dorsey & Whitney LLP | European Union | 22 Jun 2012
A subsidiary of commodities trader Glencore has been accused of bribing a European Union official in exchange for market sensitive information.
Dorsey & Whitney LLP | USA | 22 Jun 2012
In February 2012, the SEC brought FCPA claims against three oil services executives associated with Noble Corporation: Thomas O’Rourke, Mark Jackson and James Ruehlen.
Dorsey & Whitney LLP | USA | 17 May 2012
Bristol-Myers Squibb has confirmed that the SEC is investigating its sales and marketing practices in various countries.